share_log

拓新药业(301089.SZ)：积极开展合成生物学相关技术在核苷、核苷酸类产品领域的应用研究

Tuoxin Pharmaceutical (301089.SZ): Actively carry out research on the application of synthetic biology-related technologies in the field of nucleosides and nucleotide products

Gelonghui Finance ·  May 8 07:30

On May 8, Gelonghui | Tuoxin Pharmaceutical (301089.SZ) announced abnormal stock trading fluctuations. Recently, the company noticed that the Internet and some media published reports on “synthetic biology.” Guided by the principles of systems biology and engineering, synthetic biology takes genomic and biochemical molecular synthesis as the core technology. Through biochemistry, biophysics, and bioinformatics, it continuously designs, transforms, and reshapes biomolecules, biological components, and biological differentiation processes, laying a solid foundation for constructing bioactive biological elements, systems, and artificial cells or organisms. In the medical field, synthetic biology is widely used and has broad prospects. Currently, the company is actively carrying out research on the application of synthetic biology-related technologies in the field of nucleosides and nucleotide products. The relevant technology is applied to the production of some products. In 2023, the revenue achieved by these products accounts for less than 5% of operating income, which is relatively low, and there is great uncertainty about future development.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment